Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Cave

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
International Immunopharmacology|July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective studyGiuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
Endocrine Connections|November 19, 2017
Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumoursLogan Mills, Panagiotis Drymousis, Yogesh Vashist, et al.
International Journal of Molecular Sciences|January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker StudyShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Neuroendocrinology|June 22, 2021
Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour MicroenvironmentLulu Tanno, Salma Naheed, Jonathan Dunbar, et al.
BMJ Open|November 22, 2023
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centresDean Fennell, Daniel Griffiths, Zina Eminton, et al.
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
NPJ Precision Oncology|March 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancerGary Middleton, Helen L Robbins, Peter Fletcher, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
International Immunopharmacology|July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective studyGiuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
Endocrine Connections|November 19, 2017
Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumoursLogan Mills, Panagiotis Drymousis, Yogesh Vashist, et al.
International Journal of Molecular Sciences|January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker StudyShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Neuroendocrinology|June 22, 2021
Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour MicroenvironmentLulu Tanno, Salma Naheed, Jonathan Dunbar, et al.
BMJ Open|November 22, 2023
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centresDean Fennell, Daniel Griffiths, Zina Eminton, et al.
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
NPJ Precision Oncology|March 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancerGary Middleton, Helen L Robbins, Peter Fletcher, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Pageof 4